Skip to Content

Qiagen NV QGEN

Morningstar Rating
$41.45 +0.29 (0.70%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

Company Report

Qiagen Earnings: 2023 Outlook Intact Even as Reset Continues

Qiagen's third-quarter results mildly exceeded expectations, even when considering the significant COVID-19-related declines versus a tough comparable period in 2022. Positively, management maintained its 2023 guidance, despite headwinds faced by the life science and diagnostic industry. At first glance, we do not anticipate changing our fair value estimate, which remains moderately above recent trades. Also, while our moat rating remains none, we recognize that Qiagen's operations have improved substantially in recent years even when excluding COVID-19-related demand, and we expect Qiagen to remain economically profitable throughout our five-year forecast period.

Price vs Fair Value

QGEN is trading at a 20% discount.
Price
$41.45
Fair Value
$14.00
Uncertainty
Medium
1-Star Price
$85.90
5-Star Price
$82.30
Economic Moat
Ktns
Capital Allocation
Pqjjgqcdf

Bulls Say, Bears Say

Bulls

Qiagen’s long-term growth prospects in the life science and diagnostic markets will not dissolve just because the pandemic turns into an endemic situation.

Bears

Competitive threats in Qiagen's chosen fields, particularly diagnostics, may always remain high given the risk of disruptive innovation from new and established organizations.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$41.16
Day Range
$40.7841.48
52-Week Range
$34.7451.05
Bid/Ask
$0.00 / $59.00
Market Cap
$9.46 Bil
Volume/Avg
972,442 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
20.22
Price/Sales
4.89
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
6,000

Competitors

Valuation

Metric
QGEN
ILMN
DHR
Price/Earnings (Normalized)
20.22126.2024.03
Price/Book Value
2.562.953.15
Price/Sales
4.893.885.60
Price/Cash Flow
14.5129.7119.16
Price/Earnings
QGEN
ILMN
DHR

Financial Strength

Metric
QGEN
ILMN
DHR
Quick Ratio
2.561.101.76
Current Ratio
3.741.692.26
Interest Coverage
7.10−16.2425.14
Quick Ratio
QGEN
ILMN
DHR

Profitability

Metric
QGEN
ILMN
DHR
Return on Assets (Normalized)
7.53%1.20%7.50%
Return on Equity (Normalized)
13.35%2.11%12.81%
Return on Invested Capital (Normalized)
8.41%1.58%9.02%
Return on Assets
QGEN
ILMN
DHR

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncGfyy$191.7 Bil
DHR
Danaher CorpVkfnc$165.1 Bil
IDXX
IDEXX Laboratories IncSgksbm$40.1 Bil
IQV
IQVIA Holdings IncCrmtm$39.6 Bil
A
Agilent Technologies IncMhkj$37.6 Bil
MTD
Mettler-Toledo International IncCzgtjk$23.9 Bil
ICLR
Icon PLCZhqrsgc$22.2 Bil
LH
Laboratory Corp of America HoldingsQljkb$18.6 Bil
ILMN
Illumina IncLccybz$17.4 Bil
WAT
Waters CorpLbvfv$17.1 Bil